IntercepTx Overview

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

IntercepTx General Information

Description

Developer of an orally available small-molecule therapy designed to treat chronic metabolic and inflammatory conditions. The company's drug candidate targets the RAGE/DIAPH1 pathway to address metabolic stress, inflammation, and fibrosis through a single therapeutic platform, enabling pharmaceutical and healthcare markets to treat the underlying disease progression of type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis.

Contact Information

Website
www.interceptx.co.uk
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Netherlands
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IntercepTx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 23-May-2026 Completed Out of Business
2. Early Stage VC 23-Oct-2024 Completed Startup
1. Accelerator/Incubator Completed Startup
To view IntercepTx’s complete valuation and funding history, request access »

Ready to get started?

Request a free trial

IntercepTx FAQs

  • Where is IntercepTx headquartered?

    IntercepTx is headquartered in Netherlands.

  • What industry is IntercepTx in?

    IntercepTx’s primary industry is Drug Discovery.

  • Is IntercepTx a private or public company?

    IntercepTx is a Private company.

  • What is IntercepTx’s current revenue?

    The current revenue for IntercepTx is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process